Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016

Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016
Published Jun 28, 2016
104 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016, provides in depth analysis on Human Papilloma Virus (HPV) E7 Protein targeted pipeline therapeutics.

The report provides comprehensive information on the Human Papilloma Virus (HPV) E7 Protein, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Papilloma Virus (HPV) E7 Protein targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Human Papilloma Virus (HPV) E7 Protein
- The report reviews Human Papilloma Virus (HPV) E7 Protein targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Human Papilloma Virus (HPV) E7 Protein targeted therapeutics and enlists all their major and minor projects
- The report assesses Human Papilloma Virus (HPV) E7 Protein targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Human Papilloma Virus (HPV) E7 Protein targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Human Papilloma Virus (HPV) E7 Protein
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by un

  
Source:
Document ID
GMDHC0159TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Human Papilloma Virus (HPV) E7 Protein Overview91
Therapeutics Development103
  Human Papilloma Virus (HPV) E7 Protein Products under Development by Stage of Development101
  Human Papilloma Virus (HPV) E7 Protein Products under Development by Therapy Area111
  Human Papilloma Virus (HPV) E7 Protein Products under Development by Indication121
Human Papilloma Virus (HPV) E7 Protein Pipeline Products Glance132
  Late Stage Products131
  Early Stage Products141
Human Papilloma Virus (HPV) E7 Protein Products under Development by Companies153
Human Papilloma Virus (HPV) E7 Protein Products under Development by Universities/Institutes182
Human Papilloma Virus (HPV) E7 Protein Therapeutics Assessment205
  Assessment by Monotherapy/Combination Products201
  Assessment by Route of Administration212
  Assessment by Molecule Type232
Human Papilloma Virus (HPV) E7 Protein Companies Involved in Therapeutics Development2516
  Advaxis, Inc.251
  AnGes MG, Inc.261
  Cancer Research Technology Limited271
  Etubics Corporation281
  Formune S.L.291
  Genexine, Inc.301
  Genticel S.A.311
  iBio, Inc.321
  Immunovaccine, Inc.331
  Inovio Pharmaceuticals, Inc.341
  Kite Pharma, Inc.351
  MedImmune, LLC361
  Selecta Biosciences, Inc.371
  Tomegavax, Inc.381
  Transgene SA391
  VLPbio401
Human Papilloma Virus (HPV) E7 Protein Drug Profiles4147
  Antibodies to Target E7 for HPV Associated Cancer Drug Profile411
  Aptamer to Target HPV E7 Protein for Cervical Cancer Drug Profile421
  axalimogene filolisbac Drug Profile4315
  BLSILSB-710c Drug Profile581
  Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer Drug Profile592
  CerviVax Drug Profile611
  DPXE-7 Drug Profile621
  EDA-HPVE7 Drug Profile631
  ETBX-041 Drug Profile641
  GLBL-101c Drug Profile652
  GTL-001 Drug Profile673
  GTL-002 Drug Profile701
  GX-188E Drug Profile711
  human papillomavirus [Serotype 16] vaccine Drug Profile721
  human papillomavirus vaccine Drug Profile731
  INO-3106 Drug Profile741
  INO-3112 Drug Profile752
  PVX-01 Drug Profile771
  SEL-701 Drug Profile781
  TA-CIN Drug Profile791
  TG-4001 Drug Profile802
  Vaccine for Cervical Cancer Drug Profile821
  Vaccine to Target HPV E7 Protein for Cervical Cancer Drug Profile831
  VGX-3100 Drug Profile843
  Vvax-001 Drug Profile871
Human Papilloma Virus (HPV) E7 Protein Dormant Projects882
Human Papilloma Virus (HPV) E7 Protein Discontinued Products901
Human Papilloma Virus (HPV) E7 Protein Featured News &Press Releases9112
  Jun 15, 2016: Genticel to Present Clinical Results of GTL001 at EUROGIN 2016 Congress in Salzburg, Austria911
  Jun 15, 2016: Genticel to Present Preclinical Results of GTL002 at EUROGIN 2016 Congress in Salzburg, Austria911
  Jun 13, 2016: Genticel Announces Completion of Two Major Milestones in Preparation for Phase 3 Program of GTL001911
  Jun 08, 2016: Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer921
  Jun 06, 2016: Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports931
  Jun 01, 2016: Genticel Announces Publication in Clinical Cancer Research of Phase 1 Trial Results Supporting Safety, Tolerability and Immunogenicity of GTL001941
  Apr 25, 2016: Phase II Cervical Cancer Study with Advaxis Axalimogene Filolisbac Selected for Poster Discussion Session at the 2016 ASCO Annual Meeting951
  Apr 20, 2016: Genticel Reports Additional Results at 12 Months From Phase 2 Trial of HPV Immunotherapeutic Candidate, GTL001961
  Apr 20, 2016: New Preclinical Study Shows Immunovaccine s DepoVax-based Cancer Vaccine May Improve Efficacy of Checkpoint Inhibitors971
  Apr 18, 2016: Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company s Lm Technology Platform981
  Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as Best Therapeutic Vaccine by World Vaccine Congress991
  Mar 29, 2016: Advaxis Combination Trial with MedImmune Completes First Dose-Escalation Cohort1001
  Mar 29, 2016: Inovio Updates INO-3112 HPV Immunotherapy Development Plan1011
  Mar 23, 2016: Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract1011
  Mar 07, 2016: Dosing Begins in High Dose Expansion Cohort in Phase 2 Study of Axalimogene Filolisbac in Patients With Recurrent Cervical Cancer1021
Appendix1032
  Methodology1031
  Coverage1031
  Secondary Research1031
  Primary Research1031
  Expert Panel Validation1031
  Contact Us1031
  Disclaimer1041

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Human-Papilloma-Virus-HPV-E7-Protein-Pipeline-Review-H1-2016-2088-16054>
  
APA:
Global Markets Direct - Market Research. (2016). Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Human-Papilloma-Virus-HPV-E7-Protein-Pipeline-Review-H1-2016-2088-16054>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.